Articles with public access mandates - Steve WiltonLearn more
Not available anywhere: 12
Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice
N Wein, A Vulin, MS Falzarano, CAK Szigyarto, B Maiti, A Findlay, ...
Nature medicine 20 (9), 992-1000, 2014
Mandates: US National Institutes of Health
Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials
LJ Popplewell, C Adkin, V Arechavala-Gomeza, A Aartsma-Rus, ...
Neuromuscular Disorders 20 (2), 102-110, 2010
Mandates: US National Institutes of Health
Precision medicine through antisense oligonucleotide-mediated exon skipping
D Li, FL Mastaglia, S Fletcher, SD Wilton
Trends in Pharmacological Sciences 39 (11), 982-994, 2018
Mandates: National Health and Medical Research Council, Australia
Translational development of splice-modifying antisense oligomers
S Fletcher, MI Bellgard, L Price, AP Akkari, SD Wilton
Expert opinion on biological therapy 17 (1), 15-30, 2017
Mandates: National Health and Medical Research Council, Australia
RNA splicing manipulation: strategies to modify gene expression for a variety of therapeutic outcomes
S D Wilton, S Fletcher
Current gene therapy 11 (4), 259-275, 2011
Mandates: US National Institutes of Health
Co-regulation of survival of motor neuron and Bcl-xL expression: implications for neuroprotection in spinal muscular atrophy
RS Anderton, LL Price, BJ Turner, BP Meloni, C Mitrpant, FL Mastaglia, ...
Neuroscience 220, 228-236, 2012
Mandates: National Health and Medical Research Council, Australia
Splice modification to restore functional dystrophin synthesis in Duchenne muscular dystrophy
SD Wilton, S Fletcher
Current pharmaceutical design 16 (8), 988-1001, 2010
Mandates: US National Institutes of Health
Exploring microperimetry and autofluorescence endpoints for monitoring disease progression in PRPF31-associated retinopathy
D Roshandel, JA Thompson, J Charng, D Zhang, E Chelva, ...
Ophthalmic genetics 42 (1), 1-14, 2021
Mandates: National Health and Medical Research Council, Australia
The role of D4Z4-encoded proteins in the osteogenic differentiation of mesenchymal stromal cells isolated from bone marrow
L de la Kethulle de Ryhove, E Ansseau, C Nachtegael, K Pieters, ...
Stem cells and development 24 (22), 2674-2686, 2015
Mandates: National Fund for Scientific Research, Belgium
Response to “Railroading at the FDA”
F Muntoni, S Fletcher, S Wilton
Nature Biotechnology 35 (3), 207-209, 2017
Mandates: National Institute for Health Research, UK
Optimizing splice-switching oligomer sequences using 2′-O-methyl phosphorothioate chemistry
C Adkin, S Fletcher, SD Wilton
Exon Skipping: Methods and Protocols, 169-188, 2012
Mandates: US National Institutes of Health
Skipping of duplicated dystrophin exons: In Vitro induction and assessment
K Greer, S Fletcher, SD Wilton
Exon Skipping and Inclusion Therapies: Methods and Protocols, 219-228, 2018
Mandates: National Health and Medical Research Council, Australia
Available somewhere: 70
Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2 …
S Cirak, V Arechavala-Gomeza, M Guglieri, L Feng, S Torelli, K Anthony, ...
The Lancet 378 (9791), 595-605, 2011
Mandates: British Heart Foundation
A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse
PN Porensky, C Mitrpant, VL McGovern, AK Bevan, KD Foust, BK Kaspar, ...
Human molecular genetics 21 (7), 1625-1638, 2012
Mandates: US National Institutes of Health
MicroRNAs regulate tumor angiogenesis modulated by endothelial progenitor cells
PN Plummer, R Freeman, RJ Taft, J Vider, M Sax, BA Umer, D Gao, ...
Cancer research 73 (1), 341-352, 2013
Mandates: US National Institutes of Health, Australian Research Council, National …
Proteomic profiling of antisense‐induced exon skipping reveals reversal of pathobiochemical abnormalities in dystrophic mdx diaphragm
P Doran, SD Wilton, S Fletcher, K Ohlendieck
Proteomics 9 (3), 671-685, 2009
Mandates: US National Institutes of Health, Science Foundation Ireland
Rational design of antisense oligomers to induce dystrophin exon skipping
C Mitrpant, AM Adams, PL Meloni, F Muntoni, S Fletcher, SD Wilton
Molecular Therapy 17 (8), 1418-1426, 2009
Mandates: US National Institutes of Health
Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy
C Mitrpant, P Porensky, H Zhou, L Price, F Muntoni, S Fletcher, SD Wilton, ...
PloS one 8 (4), e62114, 2013
Mandates: US National Institutes of Health, UK Medical Research Council, Wellcome Trust
Dystrophin isoform induction in vivo by antisense-mediated alternative splicing
S Fletcher, AM Adams, RD Johnsen, K Greer, HM Moulton, SD Wilton
Molecular Therapy 18 (6), 1218-1223, 2010
Mandates: US National Institutes of Health
Targeted exon skipping to address “leaky” mutations in the dystrophin gene
S Fletcher, CF Adkin, P Meloni, B Wong, F Muntoni, R Kole, C Fragall, ...
Molecular Therapy-Nucleic Acids 1, 2012
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program